Results 261 to 270 of about 59,535 (272)

Cefepime pharmacodynamics in patients with extended spectrum β-lactamase (ESBL) and non-ESBL infections

Journal of Infection, 2007
This study was designed to compare cefepime exposures with microbiological outcomes in ESBL and non-ESBL infections and determine the pharmacodynamic profiles associated with successful outcome.Cefepime pharmacodynamic exposures of unbound drug [time above MIC (fT>MIC), minimal concentration over MIC (fC(min)/MIC), and area under the curve over MIC ...
Joseph L. Kuti, David P. Nicolau, Su Young Lee   +2 more
openaire   +3 more sources

Diversity and trends in population structure of ESBL-producing Enterobacteriaceae in febrile urinary tract infections in children in France from 2014 to 2017.

Journal of Antimicrobial Chemotherapy, 2019
BACKGROUND The population structure of extraintestinal pathogenic Escherichia coli evolves over time, notably due to the emergence of antibiotic-resistant clones such as ESBL-producing Enterobacteriaceae (ESBL-E).
A. Birgy, F. Madhi, C. Jung, C. Levy, A. Cointe, P. Bidet, C. Hobson, S. Béchet, E. Sobral, H. Vuthien, A. Ferroni, S. Aberrane, G. Cuzon, L. Beraud, V. Gajdos, E. Launay, D. Pinquier, H. Haas, M. Desmarest, M. Dommergues, R. Cohen, S. Bonacorsi   +21 more
semanticscholar   +1 more source

Emergence of ESBL-producing Escherichia coli ST131-C1-M27 clade colonizing patients in Europe

Journal of Antimicrobial Chemotherapy, 2018
Background The ST131 Escherichia coli clone is associated with the global dissemination of ESBLs. It has been hypothesized that ST131 could take advantage of better colonizing abilities.
I. Merino, M. Hernández-García, M. Turrientes, B. Pérez-Viso, N. López-Fresneña, C. Díaz-Agero, F. Maechler, Carolina Fankhauser-Rodriguez, A. Kola, J. Schrenzel, S. Harbarth, M. Bonten, P. Gastmeier, R. Cantón, P. Ruiz-Garbajosa, Marc Desilets, Stéphanie Dul, Fabienne Scherrer-Muller, B. Huttner, I. Uçkay, V. Prendki, G. Renzi   +21 more
semanticscholar   +1 more source

Patiënt met ESBL

2017
Geachte mevrouw Abraham-Inpijn, u hebt aangeboden dat wij per mail vragen mogen stellen. Ik wil heel graag op uw aanbod terugkomen. Ik heb een patient in een verpleegkliniek. Hij komt min of meer regelmatig naar mijn praktijk voor onder andere gebitsreiniging.
openaire   +2 more sources

Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae

Infection Control & Hospital Epidemiology, 2018
OBJECTIVE To compare the epidemiology, clinical characteristics, and mortality of patients with bloodstream infections (BSI) caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (ESBL-EC) versus ESBL-producing Klebsiella pneumoniae ...
O. Scheuerman, V. Schechner, Y. Carmeli, B. Gutiérrez-Gutiérrez, E. Calbo, B. Almirante, P. Viale, A. Oliver, P. Ruiz-Garbajosa, O. Gasch, M. Gozalo, J. Pitout, M. Akova, C. Peña, J. Molina, A. Hernández-Torres, M. Venditti, N. Prim, J. Origüen, G. Bou, E. Tacconelli, M. Tumbarello, A. Hamprecht, I. Karaiskos, C. de la Calle, F. Pérez, M. Schwaber, Joaquín Bermejo, W. Lowman, P. Hsueh, Carolina Navarro-San Francisco, R. Bonomo, D. Paterson, Á. Pascual, J. Rodríguez-Baño   +34 more
semanticscholar   +1 more source

Što poslije ESBL E.coli?

2010
*
Tambić Andrašević, Arjana, Andrašević, Saša   +1 more
openaire   +1 more source

Was bedeutet ESBL?

DMW - Deutsche Medizinische Wochenschrift, 2012
Kern Wv, Martin Kaase
openaire   +3 more sources

The Control of ESBL-Producing Bacteria

2011
Infections caused by Extended Spectrum Beta Lactamase (ESBL) producing Gram-negative bacteria have emerged over the last twenty years as a major worldwide problem for treatment. Initially the ESBL enzymes of the TEM and SHV type were identified, these did not reach high rates and were most common in Klebsiella spp rather than E.coli. ESBLs of the CTX-M
openaire   +2 more sources

[ESBL and carbapenemases in Enterobacteriaceae].

Revue medicale suisse, 2015
Carbapenemase-producing enterobacteria (CPE) spread all over the world during the last years, causing serious infections with increasing frequency. Very few new drugs active against CPE are expected to be clinically available. Studies summarized in this review show that there is yet room to improve our therapeutic approaches, in the treatment of ...
A, Cherkaoui, S, Emonet, G, Renzi, A, Riat, G, Greub, J, Schrenzel   +5 more
openaire   +1 more source

Developing An ESBL Program

American Journal of Infection Control, 2012
Natalie J. Goertz, Safiyya Nazarali, Kishori Naik   +2 more
openaire   +2 more sources